Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study

These are the supplementary materials associated with the manuscript submitted to the Journal of the American Academy of Dermatology entitled “Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study”. The files include supplementary methods describing the treatment protocol, study population, and statistical analysis, a supplementary table reporting the multivariable generalized linear mixed model analysis of predictors of long-term treatment success, and a supplementary figure illustrating the study design and treatment assessment timeline. These materials provide additional methodological details and supporting analyses referenced in the main manuscript.